Research Reports

Key takeaways

Nedira Salzman-Frenkel appointed Vice President of Business Development for CDMO division.

Role focuses on sourcing contracts in pharmaceutical, nutraceutical, nutrition, and cosmetic sectors.

Brings over a decade of life sciences experience, including securing $30 million in CRO contracts.

Previously VP BD at Israeli biotech, achieving binding licensing term-sheet with global pharma.

Aligned with strategy for long-term CDMO partnerships and new facility launch next year.

Full analysis

The appointment of Nedira Salzman-Frenkel as VP of Business Development for BioHarvest's CDMO division strengthens the company's capacity to secure long-term manufacturing and development contracts. Her extensive track record, including leading a licensing deal for Phase 3 clinical development and securing $30 million in contracts at Salzman Group, positions her to drive revenue growth amid the planned launch of a new facility next year. Dr. Zaki Rakib emphasized her role in achieving revenue targets through cross-industry partnerships in pharma, nutraceuticals, nutrition, and cosmetics. This move supports BioHarvest's Botanical Synthesis platform for sustainable plant-based compounds.

BHST · BioHarvest Sciences Inc. Common Stock

Summary

Key takeaways

Full analysis